Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure

Chloe Orkin, Jonathan Schapiro, Carlo Federico Perno, Daniel R. Kuritzkes, Parul Patel, Rebecca DeMoor, David Dorey, Yongwei Wang, Kelong Han, Veerle Van Eygen, Herta Crauwels, Susan L. Ford, Christine L. Latham, Marty St. Clair, Joseph W. Polli, Simon Vanveggel, Kati Vandermeulen, Ronald D’Amico, H Garges, Andrew Zolopa, William Spreen, Jean van Wyk, Amy CutrellClinical 2023 · DOI

Abstract

The presence of ≥2 baseline factors (RPV resistance-associated mutations, A6/A1 subtype, and/or body mass index ≥30 kg/m2) was associated with increased CVF risk, consistent with prior analyses. Inclusion of initial model-predicted CAB/RPV trough concentrations (≤first quartile) did not improve the prediction of CVF beyond the presence of a combination of ≥2 baseline factors, reinforcing the clinical utility of the baseline factors in the appropriate use of CAB + RPV LA.
BibTeX
@inproceedings{orkin2023expanded,
  author = {Chloe Orkin and Jonathan Schapiro and Carlo Federico Perno and Daniel R. Kuritzkes and Parul Patel and Rebecca DeMoor and David Dorey and Yongwei Wang and Kelong Han and Veerle Van Eygen and Herta Crauwels and Susan L. Ford and Christine L. Latham and Marty St. Clair and Joseph W. Polli and Simon Vanveggel and Kati Vandermeulen and Ronald D’Amico and H Garges and Andrew Zolopa and William Spreen and Jean van Wyk and Amy Cutrell},
  title = {{Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1093/cid/ciad370},
}

Loading related content...

Figure